RU2019100102A - Гуманизированные и химерные моноклональные антитела против cd81 - Google Patents
Гуманизированные и химерные моноклональные антитела против cd81 Download PDFInfo
- Publication number
- RU2019100102A RU2019100102A RU2019100102A RU2019100102A RU2019100102A RU 2019100102 A RU2019100102 A RU 2019100102A RU 2019100102 A RU2019100102 A RU 2019100102A RU 2019100102 A RU2019100102 A RU 2019100102A RU 2019100102 A RU2019100102 A RU 2019100102A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- antibody according
- seq
- paragraphs
- human
- Prior art date
Links
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 title claims 2
- 102100027221 CD81 antigen Human genes 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 102000055772 human CD81 Human genes 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351054P | 2016-06-16 | 2016-06-16 | |
| US62/351,054 | 2016-06-16 | ||
| PCT/US2017/037533 WO2017218691A1 (en) | 2016-06-16 | 2017-06-14 | Humanized and chimeric monoclonal antibodies to cd81 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019100102A true RU2019100102A (ru) | 2020-07-16 |
| RU2019100102A3 RU2019100102A3 (enExample) | 2020-10-14 |
Family
ID=60664252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019100102A RU2019100102A (ru) | 2016-06-16 | 2017-06-14 | Гуманизированные и химерные моноклональные антитела против cd81 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10815306B2 (enExample) |
| EP (1) | EP3471762A4 (enExample) |
| JP (1) | JP2019517813A (enExample) |
| CN (1) | CN109414492A (enExample) |
| BR (1) | BR112018076247A2 (enExample) |
| CA (1) | CA3027942A1 (enExample) |
| MA (1) | MA45404A (enExample) |
| RU (1) | RU2019100102A (enExample) |
| WO (1) | WO2017218691A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7697695B2 (ja) | 2020-01-21 | 2025-06-24 | タボテック バイオテクノロジー（チャンスー）カンパニー リミテッド | ＩＬ－１β受容体シグナル伝達に干渉する剤 |
| JP2025536268A (ja) | 2022-10-12 | 2025-11-05 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｃｄ８１ |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US7910100B2 (en) | 2004-10-01 | 2011-03-22 | Max-Planck-Gesellschaft zur Forderung der Wissen | Antibodies directed to the mammalian EAG1 ion channel protein |
| WO2006117782A2 (en) | 2005-05-04 | 2006-11-09 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against cd55 and cd59 and uses thereof |
| CN109485727A (zh) * | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US7858752B2 (en) | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| JP5769316B2 (ja) * | 2009-08-06 | 2015-08-26 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| US20140030771A1 (en) | 2010-06-09 | 2014-01-30 | Richard C. Yu | Compositions and methods for increasing oil production and secretion |
| CA2820134A1 (en) * | 2010-12-06 | 2012-06-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
| US8440797B2 (en) * | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
| US9725517B2 (en) * | 2012-10-26 | 2017-08-08 | Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences | Humanized monoclonal antibodies against the extracellular domain of human death receptor 5 |
-
2017
- 2017-06-14 WO PCT/US2017/037533 patent/WO2017218691A1/en not_active Ceased
- 2017-06-14 MA MA045404A patent/MA45404A/fr unknown
- 2017-06-14 JP JP2018566226A patent/JP2019517813A/ja active Pending
- 2017-06-14 US US16/308,113 patent/US10815306B2/en active Active
- 2017-06-14 EP EP17814033.1A patent/EP3471762A4/en not_active Withdrawn
- 2017-06-14 CA CA3027942A patent/CA3027942A1/en not_active Abandoned
- 2017-06-14 RU RU2019100102A patent/RU2019100102A/ru not_active Application Discontinuation
- 2017-06-14 CN CN201780040994.1A patent/CN109414492A/zh active Pending
- 2017-06-14 BR BR112018076247-4A patent/BR112018076247A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP3471762A4 (en) | 2020-03-11 |
| CN109414492A (zh) | 2019-03-01 |
| US10815306B2 (en) | 2020-10-27 |
| BR112018076247A2 (pt) | 2019-03-26 |
| RU2019100102A3 (enExample) | 2020-10-14 |
| EP3471762A1 (en) | 2019-04-24 |
| CA3027942A1 (en) | 2017-12-21 |
| WO2017218691A1 (en) | 2017-12-21 |
| JP2019517813A (ja) | 2019-06-27 |
| MA45404A (fr) | 2019-04-24 |
| US20190177425A1 (en) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022137054A (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| US20200140512A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| IL295295A (en) | Antibodies against fcrl5 and methods of their use | |
| JP2017504578A5 (enExample) | ||
| RU2019141289A (ru) | АНТИ-SIRPα АНТИТЕЛА | |
| HRP20221141T1 (hr) | Anti-lag3 protutijela | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| JP2018510636A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2020513809A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2016512551A5 (enExample) | ||
| WO2015197582A1 (en) | Monomeric multispecific antigen binding proteins | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| JP2017149720A5 (enExample) | ||
| RU2017125758A (ru) | Антитела к с5 и способы их применения | |
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| AR084141A1 (es) | Anticuerpos neutralizadores anti-ccl20 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20211101 |